Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Vor Biopharma ( (VOR) ) has provided an announcement.
On November 10, 2025, Vor Biopharma Inc. announced an underwriting agreement for a public offering of 10 million shares of common stock at $10 per share, expected to raise approximately $93.7 million. The proceeds will be used to advance clinical development of telitacicept, including a Phase 3 trial for primary Sjögren’s Disease, and support manufacturing and pre-commercialization activities. This financial move aims to sustain the company’s operations and capital expenditures into the second quarter of 2027, potentially strengthening its position in the biotechnology sector.
The most recent analyst rating on (VOR) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.
Spark’s Take on VOR Stock
According to Spark, TipRanks’ AI Analyst, VOR is a Underperform.
Vor Biopharma faces significant financial challenges, with no revenue and ongoing losses. Technical indicators suggest weak market sentiment, and the lack of positive valuation metrics further underscores the risk. Investors should be cautious due to the high financial risk and uncertainty.
To see Spark’s full report on VOR stock, click here.
More about Vor Biopharma
Vor Biopharma Inc. operates in the biotechnology industry, focusing on the development of innovative therapies for cancer treatment. The company is primarily engaged in advancing clinical development for its lead product candidate, telitacicept, targeting conditions such as primary Sjögren’s Disease.
Average Trading Volume: 513,927
Technical Sentiment Signal: Strong Sell
Current Market Cap: $128.6M
For a thorough assessment of VOR stock, go to TipRanks’ Stock Analysis page.